Use of leptin for the treatment of fatty liver diseases and conditions

A method of increasing mean serum leptin concentration in a non-lipodystrophic subject suffering from relative leptin deficiency comprising administering a composition comprising leptin in an amount effective to increase mean serum concentration in the subject.

A method of improving hepatitic steatosis in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to improve hepatitic steatosis in the subject.

A method of improving liver function in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to improve liver function in the subject.

A method of increasing metabolic rate in a non-lipodystrophic subject suffering from relative leptin deficiency comprising administering a composition comprising leptin in an amount effective to increase mean serum concentration in the subject.

A method of modulating messenger RNA or protein expression of glucokinase, peroxisomal proliferator activated receptor α, peroxisomal proliferator activated receptor γ, PPARγ coactivator 1, pyruvate kinase, sterol regulatory element binding protein-1c, long chain and very long chain acyl-CoA dehydrogenase or stearoyl-CoA desaturase in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to modulate said messenger RNA or protein expression.

A method of modulating messenger RNA or protein expression of phosphoenoyl pyruvate kinase, microsomal transfer protein, arylacetaminde deacetylase, apolipoprotein C2, carnitine palmitoyl transferase II, or phospholipase D1 in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to modulate said messenger RNA or protein expression.

Use of leptin in the production of a medicament for the treatment of a fatty liver condition in a non-lipodystrophic subject.

Use of leptin in the production of a medicament for increasing mean serum leptin concentration in a non-lipodystrophic subject suffering from relative leptin deficiency.

Use of leptin in the production of a medicament for improving hepatitic steatosis in a non-lipodystrophic subject suffering from hepatitic steatosis.

Use of leptin in the production of a medicament for improving liver function in a non-lipodystrophic subject suffering from decreased liver function.

Use of leptin in the production of a medicament for increasing metabolic rate in a non-lipodystrophic subject suffering from relative leptin deficiency.

Use of leptin in the production of a medicament for modulating messenger RNA or protein expression of glucokinase, peroxisomal proliferator activated receptor α, peroxisomal proliferator activated receptor γ, PPARγ coactivator 1, pyruvate kinase, sterol regulatory element binding protein-1c, long chain and very long chain acyl-CoA dehydrogenase or stearoyl-CoA desaturase in a non-lipodystrophic subject.

Use of leptin in the production of a medicament for modulating messenger RNA or protein expression of phosphoenoyl pyruvate kinase, microsomal transfer protein, arylacetaminde deacetylase, apolipoprotein C2, carnitine palmitoyl transferase II, or phospholipase D2 in a non-lipodystrophic subject.